Abstract 1869P
Background
Despite the plethora of patient (pt) communication studies in the past decade, many of them include a diverse and heterogeneous pt and physician cohort. Thus, this single-centre prospective study aimed to measure gastrointestinal (GI) cancer pts' understanding of the information discussed during their first medical oncology visit and their satisfaction with the communication from subspecialized GI medical oncologists.
Methods
Between January and August 2021, chemotherapy-naïve pts in the gastrointestinal clinic at the Princess Margaret Cancer Centre (PMCC), Toronto, Canada, were consecutively approached within 24 hours of their initial consultation to complete a paper-based questionnaire about their understanding of their cancer (diagnosis, treatment plan/intent, prognosis) and satisfaction with the communication. GI medical oncologists concurrently completed a similar questionnaire. Pt and physician responses were compared to assess the degree of concordance. Uni/multivariable analyses were performed to identify pt/physician-based factors associated with concordance levels and pt satisfaction.
Results
A total of 184 matched pt-physician surveys were completed. The concordance rates for understanding of diagnosis, treatment plan, treatment intent, and prognosis were 92.9%, 59.2%, 66.8%, and 59.8%, respectively. Pts who reported treatment intent to be unclear at the time of the consultation were independently associated with lower satisfaction scores compared to those who reported their treatment intent to be curative (p=0.014). There was no statistical significance between patient satisfaction and whether prognosis was disclosed (p=0.08). Table: 1869P
N=184 | Fully concordant, n (%) | Partially concordant, n (%) | Fully discordant, n (%) | Missing, n (%) |
Diagnosis | 171 (92.9) | N/A | 10 (5.4) | 3 (1.6) |
Treatment Plan | 109 (59.2) | 75 (40.8) | 0 (0.0) | 0 (0.0) |
Treatment Intent | 123 (66.8) | N/A | 55 (29.9) | 6 (3.3) |
Prognosis | 110 (59.8) | N/A | 65 (35.3) | 9 (4.9) |
Conclusions
Pt understanding of treatment intent and prognosis after the first medical oncology consultation remain low. Further studies on the effectiveness of consultation aids in this setting are needed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Princess Margaret Cancer Foundation.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1999P - IMreal Cohort 4: Third interim analysis of efficacy and safety in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) receiving atezolizumab plus carboplatin and etoposide (atezo + CE) as first-line (1L) therapy under real-world conditions (RWCs)
Presenter: Sanjay Popat
Session: Poster session 05
2000P - Efficacy and safety of thoracic radiotherapy after first-line immunotherapy in extensive stage small cell lung cancer: A multi-center retrospective study
Presenter: Jiake Wu
Session: Poster session 05
2001P - Consolidative thoracic radiotherapy of extensive-stage small cell lung cancer in the era of chemoimmunotherapy: A retrospective analysis concerning patients from southern Italy
Presenter: Vito Longo
Session: Poster session 05
2002P - A multicentre study assessing the real-world effectiveness of first-line chemotherapy plus immunotherapy in extensive-stage small cell lung cancer (ES-SCLC) patients
Presenter: Marie Porte
Session: Poster session 05
2003P - Consolidative intrathoracic radiotherapy during maintenance first-line immunotherapy in extensive stage small cell lung cancer (ES-SCLC): A retrospective multicenter analysis of safety and efficacy
Presenter: Alessio Bruni
Session: Poster session 05
2004P - PD-L1 Inhibitors combined with whole brain radiotherapy in patients with small cell lung cancer brain metastases: Real-world evidence
Presenter: Litang Huang
Session: Poster session 05
2005P - Anlotinib combined with chemotherapy in the treatment of first-line extensive-stage small cell lung cancer (ES-SCLC): A real-world study
Presenter: Fangfang Gao
Session: Poster session 05
2006P - Immune activation effect and survival of different irradiated sites in ES-SCLC patients treated with radioimmunotherapy: A real-world analysis
Presenter: Min Wu
Session: Poster session 05
2007P - Real-world (rw) outcomes to chemoimmunotherapy and biomarker analysis in extensive-stage small cell lung cancer (ES SCLC)
Presenter: Emmanouil Panagiotou
Session: Poster session 05